Integra LifeSciences Holdings Corporation

Total Valuation

Integra LifeSciences Holdings Corporation carries a market capitalization of 1.30B, placing it among publicly traded companies globally. Its enterprise value stands at 3.17B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Integra LifeSciences Holdings Corporation currently has 77.78M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 0.84, and the price-to-book ratio stands at 1.34.

Enterprise Valuation

On an enterprise value basis, Integra LifeSciences Holdings Corporation trades at an EV/EBITDA multiple of 14.48 and an EV/FCF ratio of 0.82. The EV/Sales ratio of 1.92 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 48.38 provides insight into valuation relative to core operating earnings.

Financial Position

Integra LifeSciences Holdings Corporation maintains a current ratio of 3.60, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 196.37, indicating elevated leverage, while an interest coverage ratio of 2.38 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Integra LifeSciences Holdings Corporation has paid 7.06M in income taxes, reflecting an effective tax rate of 145.06.

Stock Price Statistics

Integra LifeSciences Holdings Corporation's stock has gained approximately 6.63265% over the past 52 weeks. The 50-day moving average sits at 17.81, while the 200-day moving average is 13.78.

Income Statement

Over the trailing twelve months, Integra LifeSciences Holdings Corporation generated 1.65B in revenue and converted that into -7.24M in net income, yielding earnings per share of -0.09. EBITDA reached 219.07M, while operating income came in at 65.56M.

Balance Sheet

Integra LifeSciences Holdings Corporation holds 274.08M in cash and equivalents against 2.05B in total debt, resulting in a net debt position of 1.66B. Total book value stands at 1.04B, with working capital of 860.60M providing operational flexibility.

Cash Flow

Integra LifeSciences Holdings Corporation produced 85.33M in operating cash flow over the past twelve months. After subtracting -59.52M in capital expenditures, free cash flow totaled 25.80M - equivalent to 0.33 per share.

Margins

Integra LifeSciences Holdings Corporation operates with a gross margin of 52.47, reflecting its pricing power and cost economics. The operating margin of 3.98 and net profit margin of -0.44 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Integra LifeSciences Holdings Corporation's most recent stock split took place on January 4, 2017 with a 1:2 split ratio.

Scores

Integra LifeSciences Holdings Corporation posts an Altman Z-Score of 2.19, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.